Judge overturns $200m award in Gilead v Merck

A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Merck to pay Gilead $14m in attorneys’ fees

20 July 2017 A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

Americas

Federal Circuit affirms Merck ‘unclean hands’ verdict

26 April 2018 The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.

Americas

US Supreme Court refuses to hear appeal against ‘unclean hands’ decision

10 January 2019 The US Supreme Court has refused to hear an appeal against a ruling that American pharmaceutical firm Merck & Co cannot collect $200 million in damages due to its misconduct during a trial.

More on this story

Americas

Merck to pay Gilead $14m in attorneys’ fees

20 July 2017 A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

Americas

Federal Circuit affirms Merck ‘unclean hands’ verdict

26 April 2018 The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.

Americas

US Supreme Court refuses to hear appeal against ‘unclean hands’ decision

More on this story

Americas

Merck to pay Gilead $14m in attorneys’ fees

20 July 2017 A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

Americas

Federal Circuit affirms Merck ‘unclean hands’ verdict

26 April 2018 The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.

Americas

US Supreme Court refuses to hear appeal against ‘unclean hands’ decision